Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Towards better decision making in growth hormone therapy.

J S Pliskin1

  • 1Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Hormone Research
|July 7, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gender differences in risk attitudes.

Advances in health economics and health services research·2014
Same author

Impact of pooling on accuracy of hepatitis B virus surface antigen screening of blood donations.

Transactions of the Royal Society of Tropical Medicine and Hygiene·2008
Same author

Feasibility and cost-benefit of implementing pooled screening for HCVAg in small blood bank settings.

Transfusion medicine (Oxford, England)·2007
Same author

Reimbursement policies, incentives and disincentives to perform laparoscopic surgery in Israel.

Health policy (Amsterdam, Netherlands)·2001
Same author

On the dilemma of preemptive kidney transplantation.

Medical decision making : an international journal of the Society for Medical Decision Making·1998
Same author

Oregon's Medicaid ranking and cost-effectiveness: is there any relationship?

Medical decision making : an international journal of the Society for Medical Decision Making·1996
Same journal

Abstracts of the LWPES/ESPE 8th Joint Meeting Global Care in Paediatric Endocrinology, in collaboration with APEG, APPES, JSPE and SLEP. New York City, New York, USA. September 9-12, 2009.

Hormone research·2011
Same journal

Abstracts of the 47th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Istanbul, Turkey. September 20-23, 2008.

Hormone research·2011
Same journal

Abstracts of the 46th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Helsinki, Finland. June 27-30, 2007.

Hormone research·2011
Same journal

Genetic and pathogenetic aspects of Noonan syndrome and related disorders.

Hormone research·2009
Same journal

Response to growth hormone in short children with Noonan syndrome: correlation to genotype.

Hormone research·2009
Same journal

Growth hormone and the heart in Noonan syndrome.

Hormone research·2009
See all related articles

When controlled trials are not feasible, decision analysis combined with cost-benefit analysis offers a preferred method for evaluating treatments like growth hormone therapy, incorporating patient quality-of-life preferences.

Area of Science:

  • Health economics
  • Decision science
  • Clinical research methodology

Background:

  • Controlled clinical trials are not always feasible or ethical.
  • Alternative data sources are crucial for treatment evaluation.
  • Growth hormone (GH) therapy requires robust assessment methods.

Purpose of the Study:

  • To present decision analysis as a preferred methodology for treatment evaluation under uncertainty.
  • To integrate cost-benefit and cost-effectiveness analyses.
  • To emphasize the importance of quality-of-life (QoL) in GH therapy assessment.

Main Methods:

  • Utilizing observational studies, meta-analyses, expert opinions, and statistical models.
  • Applying decision analysis for situations with data uncertainty.

Related Experiment Videos

  • Incorporating cost-benefit and cost-effectiveness frameworks.
  • Focusing on QoL measurement and patient preference elicitation.

    • Main Results:

    • Decision analysis provides a structured approach when RCTs are not possible.
    • Economic analyses (cost-benefit, cost-effectiveness) enhance treatment evaluation.
    • Quantifying QoL and patient preferences is vital for GH therapy.

    Conclusions:

    • Decision analysis is a valuable tool for evaluating therapies like GH, especially with limited trial data.
    • Integrating economic and QoL factors leads to more comprehensive treatment assessments.
    • Patient-centered outcomes are essential for informed healthcare decisions.